(Q55042739)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17117297%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

title

Selective estrogen receptor modulators (SERMS) (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17117297%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17117297%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

author name string

Adolfo Diez-Perez

series ordinal

1

1 reference

16 June 2018

http://europepmc.org/abstract/MED/17117297

publication date

1 August 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17117297%20AND%20SRC:MED&resulttype=core&format=json

Arquivos Brasileiros de Endocrinologia e Metabologia

22 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17117297%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

volume

50

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17117297%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17117297%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

page(s)

720-734

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17117297%20AND%20SRC:MED&resulttype=core&format=json

A receptor molecule for estrogens: isolation from the rat uterus and preliminary characterization

22 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400017

Female steroid hormones and target cell nuclei

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400017

The steroid and thyroid hormone receptor superfamily

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400017

The role of oestrogen and progesterone receptors in human mammary development and tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400017

Estrogen receptor beta in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400017

Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400017

Generation and reproductive phenotypes of mice lacking estrogen receptor beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400017

Postnatal sex reversal of the ovaries in mice lacking estrogen receptors alpha and beta.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400017

Estrogen receptor null mice: what have we learned and where will they lead us?

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400017

Cloning of a novel receptor expressed in rat prostate and ovary

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400017

Gene regulation by steroid hormones

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400017

Interaction of steroid hormone receptors with the transcription initiation complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400017

Characterization and colocalization of steroid binding and dimerization activities in the mouse estrogen receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400017

Estrogen receptor variants in clinical breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400017

Nonnuclear actions of estrogen

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400017

Acute relaxant effects of 17-beta-estradiol through non-genomic mechanisms in rabbit carotid artery

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400017

Nongenomic mechanisms of endothelial nitric oxide synthase activation by the selective estrogen receptor modulator raloxifene

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400017

Raloxifene improves endothelial dysfunction in hypertension by reduced oxidative stress and enhanced nitric oxide production

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400017

Molecular basis of agonism and antagonism in the oestrogen receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400017

Biomedicine. Defining the "S" in SERMs

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400017

The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400017

Elucidation of the molecular mechanism of action of selective estrogen receptor modulators

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400017

Estradiol and selective estrogen receptor modulators differentially regulate target genes with estrogen receptors alpha and beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400017

Advances in the science of estrogen receptor modulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400017

Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400017

Tamoxifen--an update on current data and where it can now be used

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400017

Tamoxifen and toremifene in breast cancer: comparison of safety and efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400017

Side effects of adjuvant treatment of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400017

Comparison of the effects of EM-652 (SCH57068), tamoxifen, toremifene, droloxifene, idoxifene, GW-5638 and raloxifene on the growth of human ZR-75-1 breast tumors in nude mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400017

In vitro and in vivo biologic effects of Ospemifene (FC-1271a) in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400017

Clomiphene analogs with activity in vitro and in vivo against human breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400017

Effects of a new selective estrogen receptor modulator (MDL 103,323) on cancellous and cortical bone in ovariectomized ewes: a biochemical, histomorphometric, and densitometric study

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400017

Recovery of proximal tibia bone mineral density and strength, but not cancellous bone architecture, after long-term bisphosphonate or selective estrogen receptor modulator therapy in aged rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400017

Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400017

Chemoprevention of mammary carcinogenesis in the rat: combined use of raloxifene and 9-cis-retinoic acid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400017

The preventive and interventional effects of raloxifene analog (LY117018 HCL) on osteopenia in ovariectomized rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400017

Effects of CP-336,156, a new, nonsteroidal estrogen agonist/antagonist, on bone, serum cholesterol, uterus and body composition in rat models

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400017

Lasofoxifene (CP-336,156) protects against the age-related changes in bone mass, bone strength, and total serum cholesterol in intact aged male rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400017

Design, synthesis, and preclinical characterization of novel, highly selective indole estrogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400017

Bazedoxifene acetate: a selective estrogen receptor modulator with improved selectivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400017

Centchroman, a selective estrogen receptor modulator, as a contraceptive and for the management of hormone-related clinical disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400017

Adverse events that are associated with the selective estrogen receptor modulator levormeloxifene in an aborted phase III osteoporosis treatment study

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400017

Effects of SP500263, a novel selective estrogen receptor modulator, on bone, uterus, and serum cholesterol in the ovariectomized rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400017

EM-652 (SCH57068), a pure SERM having complete antiestrogenic activity in the mammary gland and endometrium

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400017

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400017

Breast cancer and hormone-replacement therapy in the Million Women Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400017

Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400017

Dual-energy x-ray absorptiometry of raloxifene effects on the lumbar vertebrae and femora of ovariectomized rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400017

Microdamage and bone strength

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400017

In vitro anti-resorptive activity and prevention of ovariectomy-induced osteoporosis in female Sprague-Dawley rats by ormeloxifene, a selective estrogen receptor modulator.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400017

Long-term dosing of arzoxifene lowers cholesterol, reduces bone turnover, and preserves bone quality in ovariectomized rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400017

Novel therapies for osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400017

A new selective estrogen receptor modulator HMR-3339 fully corrects bone alterations induced by ovariectomy in adult rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400017

Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400017

Tamoxifen and bone metabolism in postmenopausal low-risk breast cancer patients: a randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400017

The effect of tamoxifen on bone mineral content in premenopausal women with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400017

Efficacy and safety of raloxifene 60 milligrams/day in postmenopausal Asian women

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400017

Anti-vertebral fracture efficacy of raloxifene: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400017

Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400017

Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400017

Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to Evista (CORE) study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400017

Early effects of raloxifene on clinical vertebral fractures at 12 months in postmenopausal women with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400017

Effect of raloxifene on the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis: a reanalysis of the Multiple Outcomes of Raloxifene Evaluation trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400017

Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400017

Bone histomorphometric and biochemical marker results of a 2-year placebo-controlled trial of raloxifene in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400017

Osteoporosis prevention, diagnosis, and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400017

Is the paradigm shifting?

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400017

Separate effects of osteoporosis and density on the strength and stiffness of human cancellous bone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400017

Human vertebral body apparent and hard tissue stiffness.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400017

Aging and matrix microdamage accumulation in human compact bone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400017

Aging of microstructural compartments in human compact bone

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400017

Bone loss and bone size after menopause

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400017

Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400017

Bone density at various sites for prediction of hip fractures. The Study of Osteoporotic Fractures Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400017

Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400017

Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400017

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400017

Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400017

Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400017

Pathogenesis of bone fragility in women and men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400017

Biomechanics of bone: determinants of skeletal fragility and bone quality

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400017

Contribution of raloxifene and calcium and vitamin D3 supplementation to the increase of the degree of mineralization of bone in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400017

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400017

Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400017

Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400017

Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400017

The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400017

The Effects of Parathyroid Hormone, Alendronate, or Both in Men with Osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400017

Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400017

Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400017

Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400017

The cerebrovascular risks associated with tamoxifen use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400017

Safety assessment of raloxifene over eight years in a clinical trial setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400017

Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400017

Effect of raloxifene on cardiovascular adverse events in postmenopausal women with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400017

A selective estrogen receptor modulator for the treatment of hot flushes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400017

Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400017

Uterine sarcoma associated with tamoxifen use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400017

The effect of raloxifene on the incidence of ovarian cancer in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400017

Cognitive function in postmenopausal women treated with raloxifene

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400017

The two native estrogen receptor forms of 8S and 4S present in cytosol from human uterine tissues display opposite reactivities with the antiestrogen tamoxifen aziridine and the estrogen responsive element

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400017

10.1590/S0004-27302006000400017

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17117297%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

1 reference